Motolimod

Drug Profile

Motolimod

Alternative Names: VTX-2337

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer VentiRx Pharmaceuticals
  • Class Amides; Antineoplastics; Benzazepines; Pyrrolidines; Small molecules
  • Mechanism of Action Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Breast cancer; Lymphoma
  • Discontinued B cell lymphoma

Most Recent Events

  • 14 Feb 2017 VentiRx Pharmaceuticals has been acquired by Celgene Corporation
  • 07 Oct 2016 Efficacy and safety data from a phase II trial in Head and neck cancer presented at the the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Sep 2016 VentiRx Pharmaceuticals completes a phase II trial in Head and neck cancer (Combination therapy, Recurrent, Metastatic disease) in USA (NCT01836029)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top